Navigation Links
Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
Date:5/8/2012

CAMBRIDGE, Mass., May 8, 2012 /PRNewswire/ -- Eutropics Pharmaceuticals today announced that the United States Patent and Trademark Office has issued patent number 8,168,755 entitled, "Antibodies specific to heterodimers of Bcl-2 family and uses thereof."

The patent provides a novel method for extending Eutropics' BH3 profiling technology, which is exclusively licensed from the Dana Farber Cancer Institute. This technology assesses the ability of a key part of the cancer cell to respond to chemotherapies. This understanding provides a powerful tool for physicians to know ahead of time if a particular cancer treatment will, or will not work in a given patient and can be used to guide the use of existing drugs. This new invention by Eutropics provides a method for extending utility of the technology within solid tumors.

Eutropics is currently involved in the commercialization of the BH3 profiling assay. The test is being developed for use in guiding treatments for multiple myeloma and acute myelogenous leukemia patients as well as solid cancers. This work is being done in collaboration with the Dana Farber Cancer Institute, UMass Worcester Medical School, MD Anderson Cancer Center, and the NCI/NIH.

Michael Cardone, Co-Founder and CEO of Eutropics commented, "We are very pleased with the progress being made toward the commercial development of BH3 profiling at Eutropics. Gaining protection on this new intellectual property will help extend the process into a broader range of oncology indications. The company has made excellent progress in our clinical studies and is working very hard to provide a tool to help physicians acquire this diagnostic test that will help guide the use of chemotherapies, ultimately leading to better patient outcomes."

Eutropics Pharmaceuticals was founded on research and technology that will enable delivery of personalized medicines to patients suffering from cancer. They seek to displace current treatment paradigms by guiding the use of novel therapies tailored to an individual's cancer profile identified by the proprietary BH3 profiling diagnostic technology. This personalized approach utilizing unique diagnostics and therapeutics should result in more effective treatments and reduce unnecessary suffering.


'/>"/>
SOURCE Eutropics Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Syndax Pharmaceuticals Appoints Arlene Morris as CEO
4. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
5. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
7. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
8. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
9. Swedish Bactiguard to Enter Into an Exclusive Distribution Agreement With Cadila Pharmaceuticals
10. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
11. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Md. (PRWEB) , ... October 11, 2017 , ... ... digital pathology, announced today it will be hosting a Webinar titled, “Pathology is ... Advanced Pathology Associates , on digital pathology adoption best practices and how Proscia ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study ... in frozen and fresh in vitro fertilization (IVF) transfer cycles. The ... IVF success. , After comparing the results from the fresh and frozen transfer ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology:
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):